Cayuga Biotech
9 employees on LinkedIn · 2 known investors
Find your way into Cayuga Biotech
1,773 people in our graph share verified history with the Cayuga Biotech team — schools, employers, funds. One of them is your warm intro.
Mike Zakunlockedknows Damien Kudela · together at Cornell (overlapped)
×6knows the team · via Cornell
×4knows the team · via UC Santa Barbara
knows the team · via U.S. Department of State
Cayuga Biotech is a clinical-stage biotechnology company developing therapeutics for hemorrhage and blood-clotting-related conditions, with a lead candidate CAY001. It focuses on the hemostasis and thrombosis space, drawing on materials chemistry and translational medicine.
Founders & leadership
DK
Damien KudelainFounder, Chief Science OfficerDamien Kudela holds a PhD in Materials Chemistry and previously worked in analysis for the US State Department. He founded Cayuga Biotech to develop hemostasis-promoting therapeutics, building on research from his doctoral work on nanoparticles designed to accelerate coagulation at injury sites.
KP
Kyle PloenseinCo-founderKyle Ploense is co-founder of Cayuga Biotech and has conducted research in neuroscience, hematology, and biosensing, with experience designing pre-clinical and clinical study protocols and IND-enabling toxicology and pharmacology studies for FDA submissions. He has over a decade of experience teaching and mentoring in academic and industry settings.
AA
Andrea Ashford-HicksinChief Executive Officer
Investors · 2
In the news
Frequently asked questions
- What does Cayuga Biotech do?
- Cayuga Biotech is a clinical-stage biotechnology company developing therapeutics for hemorrhage and blood-clotting-related conditions, with a lead candidate CAY001. It focuses on the hemostasis and thrombosis space, drawing on materials chemistry and translational medicine.
- Who founded Cayuga Biotech?
- Cayuga Biotech was founded by Damien Kudela, Kyle Ploense.
- Who are Cayuga Biotech's investors?
- Cayuga Biotech's investors include SOSV, TBD Angels.